Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 5.0 | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.86 | 1.36 |
NAV | ₹20.34 | ₹203.30 |
Fund Started | 16 Aug 2022 | 07 May 2007 |
Fund Size | ₹4075.13 Cr | ₹89383.23 Cr |
Exit Load | Exit load of 1%, if redeemed within 1 month. | Exit load of 1% if redeemed within 1 year. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 13.95% | 12.58% |
3 Year | 25.65% | 26.04% |
5 Year | - | 28.35% |
1 Year
3 Year
5 Year
Equity | 96.03% | 93.94% |
Cash | -5.20% | 6.06% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Muthoot Finance Ltd. | 3.58% |
Max Financial Services Ltd. | 3.33% |
Bharti Hexacom Ltd. | 3.22% |
Fortis Healthcare Ltd. | 3.05% |
Persistent Systems Ltd. | 2.92% |
The Phoenix Mills Ltd. | 2.85% |
Coforge Ltd. | 2.52% |
The Federal Bank Ltd. | 2.48% |
Tube Investments Of India Ltd. | 2.35% |
PB Fintech Ltd. | 2.26% |
Name | Assets |
|---|---|
Max Financial Services Ltd. | 4.46% |
AU Small Finance Bank Ltd. | 3.70% |
Indian Bank | 3.54% |
The Federal Bank Ltd. | 3.38% |
Balkrishna Industries Ltd. | 3.37% |
Fortis Healthcare Ltd. | 3.19% |
Coforge Ltd. | 3.11% |
Hindustan Petroleum Corporation Ltd. | 2.96% |
Glenmark Pharmaceuticals Ltd. | 2.67% |
Ipca Laboratories Ltd. | 2.52% |
Name | Trupti Agrawal | Chirag Setalvad |
Start Date | 15 May 2024 | 28 Jun 2014 |
Name
Start Date
Description | The Scheme is to seek to generate capital appreciation by actively investing in and managing a diversified portfolio primarily composed of mid-cap stocks. | The scheme seeks to provide long-term capital appreciation/income by investing predominantly in Mid-Cap companies. |
Launch Date | 16 Aug 2022 | 07 May 2007 |
Description
Launch Date